Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 21.11% year-on-year.
Overvalued
The company’s latest PE is 47.74, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 539.60M shares, decreasing 2.34% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 1.02M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.37.